Regenxbio Inc (NAS:RGNX)
$ 7.41 -0.46 (-5.84%) Market Cap: 367.13 Mil Enterprise Value: 218.52 Mil PE Ratio: 0 PB Ratio: 1.22 GF Score: 65/100

Regenxbio Inc at Bank of America Biotech SMID Cap Conference Transcript

Dec 08, 2022 / 03:50PM GMT
Release Date Price: $22.56 (+0.67%)
Operator

Ladies and gentlemen, the program is about to begin. (Operator Instructions)

At this time, it is my pleasure to turn the program over to your host, Alec Stranahan.

Alec Warren Stranahan
BofA Securities, Research Division - Associate

All right. Great. Hey, everyone. Good morning, and welcome to Day 2 of the 2022 Bank of America's Mid-Biotech Conference. Thanks for joining the session with REGENXBIO.

My name is Alec Stranahan. I'm Vice President and Senior Biotech analyst covering REGENXBIO here at BofA. And I'm pleased to be joined today by Steve Pakola, REGENXBIO's Chief Medical Officer; as well as Vit Vasista, Chief Financial Officer. Thanks, guys, for joining the conference.

Stephen Pakola
REGENXBIO Inc. - Executive VP & Chief Medical Officer

Great to be here.

Vittal K. Vasista;Alec Warren Stranahan
REGENXBIO Inc. - Executive VP & CFO;BofA Securities, Research Division - Associate

Thanks for hosting us.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot